Key Details
Price
$42.03Annual ROE
70.49%Beta
-1.01Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 12, 2024Recent annual earnings:
N/ANext ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Jun 21, 2024Analyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
WATERTOWN, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced that it has entered into a securities purchase agreement for a private investment in public equity financing (the “PIPE”) that is expected to result in gross proceeds of approximately $185.0 million.
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, Fc-relaxin fusion protein. The interim data showed that a single intravenous dose of TX45 resulted in meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”). In the trial, TX45 was well tolerated in patients with PH-HFpEF with no serious or severe adverse events.
Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension, showing promise in early clinical trials. TX45's extended half-life and monthly dosing address limitations of native relaxin, positioning it as a potential best-in-class therapeutic. With favorable phase 1a data and ongoing phase 1b and 2 trials, Tectonic's TX45 could become a market leader, potentially attracting interest from potential biopharma acquirers.
WATERTOWN, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”) a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”), today announced detailed results from the Phase 1a clinical trial of its lead asset, TX45, a long-acting, Fc-relaxin fusion protein. The poster will be presented at the American Heart Association (AHA) Scientific Sessions on November 16, 2024 from 3-4pm EST in Chicago, Illinois. Favorable topline results from the TX45 Phase 1a clinical trial were announced on September 19, 2024, along with the dose selection for the TX45 APEX Phase 2 trial that is currently underway in patients with PH-HFpEF.
Tectonic Therapeutic's lead candidate TX45 showed positive phase 1 results for Group 2 Pulmonary Hypertension, driving the stock up over 100% in September. TX45 is an Fc-relaxin fusion molecule targeting the RXFP1 receptor, offering potential therapeutic benefits for hypertension and heart failure with preserved ejection fraction (HFpEF). Tectonic has a solid financial position with a market cap of $551mn, $185mn in cash reserves, and a cash runway extending into 2027.
TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the Phase 2 clinical trial
Tectonic Therapeutic (NASDAQ: TECX ) just reported results for the second quarter of 2024. Tectonic Therapeutic reported earnings per share of -$4.34.
WATERTOWN, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will present at the 2024 Wells Fargo Healthcare Conference being held in Boston on September 4-6, 2024 and participate in the Morgan Stanley 22nd Annual Global Healthcare Conference being held in New York on September 4-6, 2024.
FAQ
- What is the ticker symbol for Tectonic Therapeutic?
- Does Tectonic Therapeutic pay dividends?
- What sector is Tectonic Therapeutic in?
- What industry is Tectonic Therapeutic in?
- What country is Tectonic Therapeutic based in?
- Is Tectonic Therapeutic in the S&P 500?
- Is Tectonic Therapeutic in the NASDAQ 100?
- Is Tectonic Therapeutic in the Dow Jones?
- When was Tectonic Therapeutic's last earnings report?
- When does Tectonic Therapeutic report earnings?
- Should I buy Tectonic Therapeutic stock now?